Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17205680 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2IRAK4RORCKDM4EALDH1A1 | |
| SCHEMBL20503412 | 0.83 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1HRH3 | |
| SCHEMBL26105692 | 0.79 | HPGD (0.38) | SMN1; SMN2KDM4EALDH1A1TSHRHPGD | |
| SCHEMBL26105695 | 0.79 | HPGD (0.38) | SMN1; SMN2KDM4EALDH1A1TSHRHPGD | |
| SCHEMBL26106259 | 0.79 | HPGD (0.38) | SMN1; SMN2KDM4EALDH1A1TSHRHPGD | |
| SCHEMBL17785641 | 0.77 | HRH3 (0.33) | HRH3 | |
| SCHEMBL224278 | 0.77 | CA1 (0.33) | SMN1; SMN2TSHR | |
| SCHEMBL986268 | 0.77 | HRH3 (0.43) | KDM4EALDH1A1HRH3 | |
| SCHEMBL3272691 | 0.77 | HRH3 (0.40) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL12022473 | 0.76 | IRAK4 (0.41) | SMN1; SMN2IRAK4KDM4EL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134091-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015164374-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 3442/4885IRAK4 4/4885RORC 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.